Trinomab Pharmaceutical

Trinomab Pharmaceutical is a clinical-stage biopharmaceutical company focused on the discovery and development of fully native human monoclonal antibodies using its proprietary HitmAb® platform. Headquartered in Zhuhai, China, the company specializes in creating recombinant antibody alternatives to traditional blood-derived immunoglobulins for infectious diseases, inflammatory disorders, and pain management. Its lead product, Siltartoxatug (Sintetol / TNM002), is a first-in-class anti-tetanus toxin monoclonal antibody that received marketing approval in China in February 2025. Trinomab maintains a robust pipeline including advanced candidates for respiratory syncytial virus (RSV) and varicella-zoster virus (VZV), aiming to provide safer and more scalable therapeutic solutions globally. The company is backed by major institutional investors including Hillhouse Capital and China Life.